Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Kuchay, Mohammad Shafi, Krishan, Sonal, Mishra, Sunil Kumar, Farooqui, Khalid Jamal, Singh, Manish Kumar, Wasir, Jasjeet Singh, Bansal, Beena, Kaur, Parjeet, Jevalikar, Ganesh, Gill, Harmendeep Kaur, Choudhary, Narendra Singh, Mithal, Ambrish·2018·Diabetes Care
DOI 10.2337/dc18-0165

Cited by (657)

Items 501–600 of 657

  1. Non-alcoholic Fatty Liver Disease
    Sangwon F. Kim, Jang Hyun Choi · 2023 · Springer eBooks
  2. Protective mechanism and clinical application of SGLT2 inhibitors in patients with type 2 diabetes mellitus complicated with abnormal liver function
    Yunhui Zhao · 2024 · International Journal of Public Health and Medical Research
  3. Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study
    Anas Ibraheem, Waseem F. Al Tameemi · 2024 · Cureus
  4. An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
    Sanjay Kumar Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, Saibal Das · 2024 · Hospital Practice
  5. Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
    Joonpyo Lee, Mi‐Seung Shin · 2025 · Cardiovascular Prevention and Pharmacotherapy
  6. Sotagliflozin provides additional benefits for high-fat diet-induced cardiac inflammatory injury by extra inhibiting P38MAPK and JNK
    Jian-Chao Luo, Le-Hao Jin, Yun-shan Zhong, Xiaoyu Xu, Zhe-Yan Zhang, Jing Chen, Zhong-xi Chen, Sen Li, Xiao-Dan Zhang, Jianchang Qian · 2025 · International Immunopharmacology
  7. The Effect of Empagliflozin on Non-alcoholic Steatohepatitis and Liver Enzymes Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial
    Khatereh Nasiri Mehr, Javad Shokry, Hemmat Gholinia Ahangar, Manijeh Ebrahimzadeh Pirshahid, Seyedeh Fatere Seyedalipour, Abdolreza Emami, Neda Meftah · 2025 · Hepatitis Monthly
  8. Diagnose und Therapie der MASLD
    Paul Horn, Frank Tacke · 2025 · Die Innere Medizin
  9. Non-alcoholic fatty liver disease as a link in the cardiometabolic continuum: Focus on hypertriglyceridemia
    Tatiana Yu. Demidova, Багилова Амина Расуловна, Ушанова Фатима Омариевна · 2025 · FOCUS Endocrinology
  10. Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future
    Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal · 2025 · Diabetology International
  11. Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use
    Л. Б. Лазебник, Светлана Владимировна Туркина, E. V. Golovanova · 2024 · Экспериментальная и клиническая гастроэнтерология
  12. Effect of tofogliflozin on obesity-related health problems in patients with type 2 diabetes and overweight or obesity—a post-hoc sub-analysis of the UTOPIA study
    Naoto Katakami, Tomoya Mita, Takafumi Masuda, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA Study Investigators · 2025 · Diabetology International
  13. Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study
    Alfredo Caturano, Raffaele Galiero, Vittorio Simeon, Carlo Acierno, Davide Nilo, Aldo Marrone, Maria Consiglia Trotta, Erica Vetrano, Celestino Sardu, Vincenzo Russo et al. · 2025 · Nutrition Metabolism and Cardiovascular Diseases
  14. Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review
    Shaikh Hamiz ul Fawwad, Manthanbhai S. Patel, Sonia Dziugieł, Razan Alfaki, Muhammad Tamoor Akhtar Shaikh, Kapil Khanal, Pratik Lamichhane, Shankar Baral · 2025 · Annals of Medicine and Surgery
  15. Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection
    Siyu Li, Yaqi Wang, Quan Gong · 2025 · Frontiers in Endocrinology
  16. Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
    Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Arquivos Brasileiros de Cardiologia
  17. Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
    Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Arquivos Brasileiros de Cardiologia
  18. Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
    Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Revista Brasileira Ginecologia e Obstetrícia
  19. Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice
    Huina Zhang, Peng Liu, Yaxuan Deng, Li Wu, Orion R. Fan, Yanling Cui, Chunxue Zhang, Wenmin Zhu, Yi Eve Sun, Chuwen Lin et al. · 2025 · Stem Cell Research & Therapy
  20. Comparative Effectiveness of Empagliflozin and Dapagliflozin in Chinese Patients with Type 2 Diabetes Mellitus
    Panpan Zheng, Yanan Zhao, Meng Du, Jing-Hua Sun, Zhe Zhao, Jing-Tao Liu, Lili Zhang, Zan-Chao Liu, Xian Xiu · 2025 · Hospital Pharmacy
  21. Role of sodium-glucose cotransporter 2 inhibitors in liver diseases
    Prajna Anirvan, Suprabhat Giri, Sayan Malakar, Dibya Lochan Praharaj · 2025 · World Journal of Experimental Medicine
  22. Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction–associated steatohepatitis (MASH): A real-world data analysis
    Elizabeth Beyene, Lakshmi Gayathri Chirumamilla, Mekdem Bisrat, Allan Bowen, Yonas Fetle, Brandon Wilkerson, Addishiwot T Wudeneh, Syed Fahad Gillani, Daniel A. Larbi, Miriam B Michael · 2026 · Clinics and Research in Hepatology and Gastroenterology
  23. A Drug Repositioning Approach: Antidiabetic Empagliflozin May Be a Potential Drug for the Treatment of ALS
    Selma Sezen, Feyza Burul · 2026 · Recent trends in pharmacology.
  24. Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials
    Khalid I. AlHussaini · 2026 · Frontiers in Medicine
  25. A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome
    Xuechun Ren, Di Gao, Rong Yun, Xinyang Liu, Chenna Di, Zeyu Hu, Xinyuan Zhang, Zhongmin Tian, Zhe Yang · 2026 · Nature Communications
  26. Redox Imbalance in the Cardiohepatic Syndrome: The Emerging Role of Oxidative Stress in Cirrhosis-Associated Cardiac Dysfunction
    Nikola Blagojevic, Dragana Blagojevic, Ana Matovic, Marko Cvrkotic, Marija Marjanovic-Haljilji, Aleksandra Šljivić, Ana Ilić, Nataša Cvetinovic, i Nikola Nenadic, Marko D. Djuric et al. · 2026 · Antioxidants
  27. Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease
    Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco et al. · 2026 · Biomolecules
  28. Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies
    Xiang-jing Chai, Gong Wei, Wei Chen, Dong-Yu Min, Yang Wang, Le Guan · 2026 · Frontiers in Pharmacology
  29. Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study
    Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna G. Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, DAKSHATA A. PADHYE et al. · 2026 · Frontiers in Clinical Diabetes and Healthcare
  30. Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD
    Kohei Yasuda, Noriho Iida, Yumie Takeshita, Yusuke Masuo, Masao Honda, Toshinari Takamura, Taro Yamashita · 2026 · Journal of Gastroenterology
  31. Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye
    Hilmi Erdem Sümbül, Ali Kırık, Selçuk Yaylacı, Alihan Oral, Sıbel Ocak Serın, Kubilay Issever, Nizameddin Koca, Ahmet Aydin, İsmail Demir, Nevzat Gözel et al. · 2026 · Hepatology International
  32. Metabolic control by liver–kidney crosstalk and glucagon in health and disease
    Volker Vallon, Nicolai J. Wewer Albrechtsen · 2026 · Nature Reviews Nephrology
  33. The Effects of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2-i) on Fatty Liver, Steato-Hepatitis, Liver Fibrosis, and Hepatocellular Carcinoma-A Review
    Hyder Osman Mirghani, Thomas Antony Thaniyath, Fakhralddin Abbas Elfakki · 2019 · Biology and Medicine
  34. Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report
    Toshiharu Ishizuka, Yoshiharu Tokuyama, Atsuya Horie, Azuma Kanatsuka · 2020 · Diabetology International
  35. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
    Pankaj Aggarwal, Tamneet Singh, Naim Alkhouri · 2020 · Current Hepatology Reports
  36. Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Andrey E. Bagriy, A.D. Zubov, M V Khomenko, Е. С. Михайличенко, Е. А. Пылаева, N. A. Khaustova, E. V. Bryukhovetskaya · 2021 · Russian Journal of Gastroenterology Hepatology Coloproctology
  37. A Rare Case of Drug Induced Liver Injury Secondary to Empagliflozin
    Ana Luísa Nunes, Daniela Santos, Carolina Figueiredo, D. Ferreira, Jandira Lima, Arsénio Santos · 2021 · Medicina Interna
  38. Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?
    Mohammad Shafi Kuchay, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  39. Correlation of PCSK1 with nonalcoholic fatty liver disease in a Han Chinese population: a case-control observational study
    Xiao Yang, Fan Yuan, Na Wu, Decheng Ren, Liangjie Liu, Yan Bi, Lei Ji, Ke Qing Han, Mofan Feng, Kai Su et al. · 2022 · Journal of Bio-X Research
  40. The changes of oxidative stress markers and vitamin E in patients with diabetes using SGLT2 inhibitors
    Banu Büyükaydın · 2023 · International journal of medical biochemistry/International journal of medical biochemistry :
  41. NAFLD, the hepatic manifestation of the metabolic syndrome
    Tirthankar Chaudhury, Lucia Brodosi, Giulio Marchesini, Sandip Kumar Mitra, Maria Letizia Petroni · 2024 · Elsevier eBooks
  42. Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study
    Naoto Katakami, Tomoya Mita, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura · 2024 · Diabetology International
  43. Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
    Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Tomohiro Otani, Takashi Kobayashi, Asako Nogami, Satoru Saito, Atsushi Nakajima · 2024 · Expert Opinion on Emerging Drugs
  44. Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study
    Muhammad Imran Butt, Gaurav Puri, Kathryn Berkman, Simon J. Ryder, Joshua Knowles, Muhammad Asif Shahzad, Muhammad Amer Malik, Noa Shalev, Jo Sexton · 2024 · Journal of Endocrinology and Metabolism
  45. The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
    Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii‐Dizgah, Afsaneh Vosughi · 2024 · Annals of Military and Health Sciences Research
  46. Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options
    Justyna Śliz, Natalia Aleksandra Popławska, Marta Skorupska, Magdalena Joanna Czeczotka, Krzysztof Woźniak, Martyna Magdalena Martka · 2024 · Quality in Sport
  47. New Perspectives on Obesity-Associated Nephropathy from Pathophysiology to Therapeutics: Revealing the Promise of GLP-1 RA Therapy
    Linan Ren, Feng Ju, Siyuan John Liu, Yunjia Cai, Xiaokun Gang, Guixia Wang · 2024 · Drug Design Development and Therapy
  48. Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Loiy Naser Alsarkhi, Sanjay Eda, Rahman Hameed Mohammed Abdul, Helai Hussaini, Olaniyi A Fadeyi, Sandipkumar S Chaudhari, Muhammad A. Rauf, Danish Allahwala · 2025 · Cureus
  49. Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders
    Andrew J. Krentz, Pierre Bédossa · 2019 · Springer eBooks
  50. Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
    Maria Apostolopoulou, Michael Roden · 2022 · Springer eBooks
  51. Metabolic effects of empagliflozine
    А. В. Кедик, O. O. Kutsin · 2022 · Diabetes Obesity Metabolic Syndrome
  52. Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
    Cătălina Mihai, Bogdan Mircea Mihai, Cristina Cijevschi Prelipcean · 2023 · Springer eBooks
  53. Effizienz antidiabetischer Kombinationstherapien bei nichtalkoholischer Fettlebererkrankung und Typ‑2‑Diabetes
    SABINE KAHL · 2018 · Der Diabetologe
  54. Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
    Dimitrios Patoulias, Maria Kalogirou · 2018 · Gastroenterology Review
  55. Das diabetische Herz und Herzinsuffizienz – Aktuelles zu Entstehung und Therapie
    Elric Zweck, Julia Szendrödi, Malte Kelm, Michael Roden · 2019 · DMW - Deutsche Medizinische Wochenschrift
  56. Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
    Pablo Toledo Frías, Raquel Campuzano Ruíz, José Antonio Alarcón Duque, Alejandro Berenguel Senén, María Rosa Fernández Olmo, Manuel Abeytua Jiménez · 2019 · REC CardioClinics
  57. Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes
    Nicola Santoro, Rachel Goldberg-Gell, Sonia Caprio · 2021 · Contemporary Endocrinology
  58. 188 腹壁ヘルニアの手術と予後( 第29回日本消化器外科学会総会)
    晴彦 渡辺, 敏明 斉藤, 淑人 有沢, 建 露木, 健之 新井, 秀浩 滝沢, 喬義 中津 · 1987 · 日本消化器外科学会雑誌
  59. From Ptolemy to Copernicus: a new proposal for the care of diabetes
    Maria Chantal Ponziani · 2019 · The Journal of AMD
  60. Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study
    Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida et al. · 2021 · SSRN Electronic Journal
  61. Around Australia – Chickens and Campylobacter
    Jillian M. Templeton, J.M. Hewitson, Philip M. Giffard, Patrick Joseph Blackall · 2014
  62. Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis
    M. V. Martjanova, M. Yu. Laevskaya, Мелтонян Ася Робертовна, Vadim Borisovich Bregovskiy, Alina Yu. Babenko · 2021 · Экспериментальная и клиническая гастроэнтерология
  63. SGLT2 Inhibitors
    Jee Hee Yoo, Jae Hyeon Kim · 2021 · Stroke revisited
  64. Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
    Kyung‐Soo Kim · 2022 · Journal of Korean Diabetes
  65. Empagliflozin in mice fed on a fast-food diet: Preliminary biochemical data
    Evangelia S. Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis-Parasidis, Eleftheria Makri, Anastasia Tsingotjidou, Angeliki Cheva, Iris Ballaouri, Spyridon Gerou, Antonis Goulas, Stergios A. Pοlyzos · 2022 · Journal of Atherosclerosis Prevention and Treatment
  66. Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit
    Max I. Egers, Marijane Hynes · 2022 · Journal of Kidney Care
  67. Medical therapy
    Janina Senn, Stefan Fischli · 2023 · Elsevier eBooks
  68. Editorial: Emerging mechanistic insights of selective and Nonselective Autophagy in liver and gut diseases and their treatment strategies in the era of COVID-19
    Md. Abdul Alim Al‐Bari, Manoj B. Menon, Nabil A. S. Eid · 2023 · Frontiers in Pharmacology
  69. RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
    Gehan Hussein Heeba, Mohamed Abolnaga, Eman Maher Othman · 2023 · Bulletin of Pharmaceutical Sciences Assiut
  70. ASSESSMENT OF PENTOXIFYLLINE EFFECTS ON LIVER STEATOSIS UTILIZING DIXON-BASED MRI TECHNIQUE; RANDOMIZED CONTROLLED STUDY
    Sahar Hossam El-Hini, Asmaa Elsayed, Ahmed Abdullah Elberry, Nadia Farouk El Ameen, Ahmed Abdel Fadil Saedii, Marwa Ibrahim, Nadia Ismail, Haitham Saeed, Hoda Rabea · 2023 · Bulletin of Pharmaceutical Sciences Assiut
  71. Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial
    Borwonkhun Tontivuthikul, Witthawat Naeowong, Weerapan Khovidhunkit · 2019 · Chula Digiverse
  72. The Use of Sodium-Glucose Cotransporter 2 Inhibitors in Non-Alcoholic Fatty Liver Disease
    Ron Hang Long Li · 2021 · Current Trends in Gastroenterology and Hepatology
  73. Comparison of semaglutide in combined with empagliflozin versus semaglutide and empagliflozin monotherapy in non-alcoholic fatty liver disease with type 2 diabetes: study protocol for a randomised controlled clinical trial
    Yuhao Lin, Zhijun Zhang, Jin-Qing Zhong, Zhiyi Wang, Yi-Ting Peng, Yan-Mei Lin, Huo-Ping Zhang, Jian-Qing Tian · 2023 · medRxiv
  74. Tratamiento farmacológico actual y futuro de la esteatosis hepática
    Núria Alonso, María Teresa Julián · 2023 · Diabetes práctica
  75. Empagliflozin Exacerbated Lipid Metabolism Disorders in Diabetic Mice
    Jianping Li, Baotong Xing, Meiling Xu, Qinyu Zhang, Jianming Guo, Jin‐Ao Duan · 2024 · SSRN Electronic Journal
  76. Usefulness of long-term administration of SGLT2 inhibitors in patients with MASLD and diabetes
    Katsunori Ishii, Miwa Kawanaka, Shintaro Oda, Minako Kimura, Mayuko Kawada, Tomohiro Tanikawa, Noriyo Urata, Ken Nishino, Mitsuhiko Suehiro, Ken Haruma et al. · 2024 · Kanzo
  77. Nonalcoholic fatty liver disease: What comes before and what are the consequences?
    Fernando Bril · 2024 · Elsevier eBooks
  78. STEATOSIC LIVER DISEASE AND CARDIOVASCULAR DISEASES: ASSOCIATION, PROGNOSIS AND TREATMENT
    Т. В. Ткаченко, Halyna Tomashkevych · 2023 · Modern medicine pharmacy and psychological health
  79. MASLD- Global prevalence, pathophysiological processes and management pathways- tackling a complex problem
    Gourdas Choudhuri, Seema R Kalel, Zubin Dev Sharma, Rinkesh Bansal · 2024 · Gastroenterology & Hepatology Open Access
  80. O RASTREAMENTO DA ESTEATOSE HEPÁTICA NO DIABETES MELLITUS TIPO 2
    Marina Corrêa da Silva, Christiane Guedes Carneiro, Louise Moreira Vieira, Marina Kengen França, Peter Allison Soares Cerqueira, Adriana Rodrigues Ferraz · 2024 · Revista Ibero-Americana de Humanidades, Ciências e Educação
  81. Diverse Clinical Effects of SGLT2 Inhibitor: Case Presentation and Literature Mini-review
    Yukio Aso, Hajime Kataoka, Saki Harada, Yu Yamasaki, Tetsuji Sugata · 2023 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  82. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
    Mohamed Abdel-Samiee, Essam Salah Ibrahim, Mohamed Kohla, Eman Abdelsameea, Mohsen Salama · 2024 · World Journal of Gastrointestinal Pharmacology and Therapeutics
  83. Efficacy of Sodium-Glucose Transporter 2 Inhibitors in the Treatment of Non-Alcoholic Fatty Liver Disease: A Meta-Analysis
    嘉豫 李 · 2024 · Advances in Analytical Chemistry
  84. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fernando Bril, Gabriela Alicia Berg, Magalí Barchuk, Juan Patricio Nogueira · 2025 · Journal of Lipid and Atherosclerosis
  85. Luseogliflozin Persistently Lowers Glycemia and Body Weight Over a Period of Two Years in Patients With Type 2 Diabetes
    Jun-ichirou Mori, Koh Yamashita, Toru Aizawa · 2025 · Cureus
  86. Beyond Glucose: Empagliflozin’s Impact on Fatty Liver in Patients with Type 2 Diabetes; A True Game Changer
    Qamar Sajad, Khurshid Ahmad Khan, Aijaz Zeeshan Khan, Danish Khan, Javeid Iqbal, Muhammad Ibrar Mustafa · 2025 · Indus journal of bioscience research.
  87. The impact of dapagliflozin on FIB-4 index over 2 years in patients with type 2 diabetes mellitus
    Semra Özkan, Deniz Gezer · 2025 · The European Research Journal
  88. A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
    Iyiad Alabdul Razzak, Imad Alabdul Razzak, Mazen Noureddin, Hirsh D. Trivedi · 2025 · Journal of Clinical Gastroenterology
  89. Asociación del síndrome de ovario poliquístico e hígado graso en mujeres: revisión de la literatura
    Diana Carolina Alfonso Vergel, Carmen Yanette Suárez Quintero · 2025 · Revista Colombiana de Gastroenterología
  90. The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 Diabetes mellitus and metabolic-associated steatotic liver disease: comment
    Yunlong Song, Rongchao Fang, Bo Yu · 2025 · Internal and Emergency Medicine
  91. FIB-4 Trajectories and Predictors of Fibrosis Response in Type 2 Diabetes Treated with SGLT2 Inhibitors: A Propensity-Matched 12-Month Study
    Nazif Yalçın, Ayşegül Ertınmaz Özkan, Gizem Zorlu Görgülügil, Nizameddin Koca · 2025 · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
  92. Association between serum albumin to creatinine ratio and non-alcoholic fatty liver disease: a longitudinal cohort study in non-obese Chinese individuals
    Weitao Wu, Donghai Wu, Fanglan Chen, Shi-Hua Ding, Ying Ying, Dayong Sun, Haofei Hu · 2025 · BMC Gastroenterology
  93. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
    Alam Zeb · 2025 · Elsevier eBooks
  94. The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study
    Hüseyin Ali Öztürk, Hilmi Erdem Sümbül · 2025 · Irish Journal of Medical Science (1971 -)
  95. Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome
    Oksana M. Drapkina, Sergey Vladimirovich Nedogoda · 2025 · Russian Journal of Cardiology
  96. Comparative Efficacy Of Remogliflozin, Telmisartan And Saroglitazar In An Experimental Rat Model Of Non-Alcoholic Fatty Liver Disease
    Guguloth Vijay Kumar, Akhilesh Mishra, Bhupinder Singh · 2025 · Research Square
  97. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Simei Huang, Yu Xi, Yanqing Hong, Chenliang Hu · 2025 · Hormone and Metabolic Research
  98. Expert Opinion of Empagliflozin Positioning in the Current Type 2 Diabetes Mellitus (T2DM) Landscape in Indian Patients
    Bipin Kumar Sethi, Ashwani Mehta, Arundhati Dasgupta, Manoj S Chawla, Nilakshi Deka, Navneet Agarwal, Chinmoy Mazumder, Ipshita Ghosh, Vishal Gala, Sameer Muchhala et al. · 2025 · Cureus
  99. Additional file 1 of The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
    Park, Jiyun, Kim, Gyuri, Bongsung Kim, Han, Kyung-Do, Kwon, So Yoon, Park, So Hee, Lee, You-Bin, Jin, Sang-Man, Kim, Jae Hyeon · 2022 · Figshare
  100. Additional file 1 of Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
    Deng, Manjun, Wen, Yonghao, Yan, JingXin, Fan, Yichen, Wang, Zhixin, Ruixia Zhang, Ren, Li, Ba, Yinggui, Haijiu Wang, Lu, Qian et al. · 2023 · Figshare